Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
Diabetes, Obesity and Metabolism · 2025-12 · 27 (12) · 6979-6987
DOI: 10.1111/dom.70096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.09.2025. Verfasst von Søren Seier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Weight Reduction Programs, Overweight. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Embla ApS.
Themen: Digitalisierung in der Pflege
Abstract (Originalsprache)
Aims
To evaluate the effectiveness of an online multidisciplinary weight loss service combining individualised semaglutide dosing with intensive behavioural therapy (IBT) in adults living with overweight or obesity. Materials and methods This retrospective cohort study included data from Danish participants enrolled in a digital weight loss programme via the Embla app between January 2022 and September 2024. The programme offered semaglutide with personalised dosing alongside evidence‐based recommendations on nutrition, exercise and habits, delivered through IBT. All data collection and monitoring was conducted via the Embla app. The primary outcome was percentage change in body weight at week 64. Secondary outcomes included semaglutide dose, proportions achieving ≥5%, ≥10%, ≥15%, or ≥20% weight loss, and weight change by baseline BMI and dose.
Results
The study included 2694 participants (78% women, mean age 46.8 ± 10.8 years, mean BMI 34.3 ± 4.8). At weeks 26, 52, and 64, the number of participants that remained in the study was: 1580, 712, and 465. Mean weight loss at week 64 was 16.7% (95% CI: −17.4 to −16.0) with a mean semaglutide dose of 1.08 mg/week (SD 0.54). A total of 98% achieved ≥5% and 82% achieved ≥10% weight loss. Weight change was consistent across BMI classes and medication doses.
Conclusions
Participants achieved clinically meaningful weight loss comparable to that seen in randomised trials, despite using lower semaglutide doses. These findings support the effectiveness of a personalised, treat‐to‐target approach integrating medical and behavioural obesity management in a digital setting. Trial registration https://osf.io/86kmc/
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Embla ApS, Copenhagen, Denmark.
- Department of Public Health, Centre for General Practice, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Søren Seier, Signe Sørensen Torekov, Henrik Gudbergsen
Förderung
- Embla ApS
Zitieren
APA
Seier, S., Stamp-Larsen, K., Jensen, S. B. K., Torekov, S. S., & Gudbergsen, H. (2025). Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic. Diabetes, Obesity and Metabolism, 27(12), 6979-6987. https://doi.org/10.1111/dom.70096
Vancouver
Seier S, Stamp-Larsen K, Jensen SBK, Torekov SS, Gudbergsen H. Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic. Diabetes, Obesity and Metabolism. 2025;27(12):6979-6987. doi:10.1111/dom.70096
BibTeX
@article{Seier2025,
author = {Seier, Søren and Stamp-Larsen, Kine and Jensen, Simon Birk Kjær and Torekov, Signe Sørensen and Gudbergsen, Henrik},
title = {Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {12},
pages = {6979--6987},
doi = {10.1111/dom.70096}
}
EUVIMED